CD274 and non-small cell lung carcinoma: On the basis of the potential immunogenic properties of anti-vascular endothelial growth factor (VEGF) inhibitors, IMpower150 investigated the role of the atezolizumab-chemotherapy combination, and the potential added benefits of bevacizumab, in the first-line setting in 1202 patients with non-squamous NSCLC and any level of PD-L1 expression [21,22].